Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura.
Ultra-Levura (Upsamedica, Spain) is a yeast (Saccharomyces boulardii) widely used as a biotherapeutic agent. To date, few adverse effects have been reported, although fungemia with Saccharomyces cerevisiae can occur in weak and immunosuppressed patients. Reported here are two cases of fungemia with Saccharomyces cerevisiae. One patient had been treated with Ultra-Levura and the other contracted the infection from the first. This is the first report of infection with Saccharomyces boulardii (Saccharomyces cerevisiae) in a patient who was not being treated with the agent.
Perapoch
J
J
Servei de Neonatologia, Hospital Materno-Infantil Vall d'Hebron, Barcelona, Spain. perapoch@yahoo.com
Planes
A M
AM
Querol
A
A
López
V
V
Martínez-Bendayán
I
I
Tormo
R
R
Fernández
F
F
Peguero
G
G
Salcedo
S
S
D005260:Female; D005657:Fungal Vaccines / Q000009:adverse effects* / Q000627:therapeutic use; D016469:Fungemia / Q000382:microbiology* / Q000635:transmission; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012441:Saccharomyces cerevisiae / Q000302:isolation & purification
D005657:Fungal Vaccines; C041317:ultra-levure